iMDx Announces $26.0 Million Registered Direct Offering

Core Viewpoint - Insight Molecular Diagnostics Inc. has announced a registered direct offering of 4,525,976 shares of common stock at an offering price of $5.75 per share, expected to raise approximately $26 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on February 12, 2026, pending customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the sole placement agent for the offering [2]. - The purchase price for pre-funded warrants is the same as the common stock price, minus an exercise price of $0.0001 per share [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, particularly for research and development in the transplantation category [2]. - The company aims to expand its GraftAssure product line to include heart transplant rejection testing, in addition to kidney transplant rejection testing [3]. Group 3: Shareholder Participation - Bio-Rad Laboratories, Inc., a significant shareholder of Insight Molecular Diagnostics, participated in the offering on the same terms as other investors [3]. Group 4: Regulatory Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on August 7, 2024 [4]. - A final prospectus supplement will be filed with the SEC and will be available on their website [4]. Group 5: Company Overview - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6]. - The company offers various products, including GraftAssureCore™, GraftAssureIQ™, and others [6].